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Clinically useful anti-tumour agents have widely differing
biochemical and molecular mechanisms of action, depending of
their target(s) among the cellular components, notably the metabo-
lism of DNA (Pinedo et al, 1997). In this respect, DNA topoiso-
merases and proteins involved in DNA repair are of particular
interest. DNA topoisomerases I (TOP1) and II (TOP2) are essen-
tial enzymes differentially regulating many aspects of the topology
of nucleic acids, including DNA replication, transcription,
chromosome structure, condensation and segregation, as well as
the organization of the nuclear matrix (Wang, 1985; Osheroff,
1989; Chen and Liu, 1994). Among several mechanisms, some
of the topoisomerase-targeting anti-tumour agents exert their
cytotoxic effects by stabilizing cleavable complexes, an otherwise
transitory step of the catalytic cycle of the topoisomerase enzyme
(Chen and Liu, 1994). From this observation, it has been proposed
that this stabilization creates persistent DNA strand breaks and,
therefore, that cells are killed because the enzyme is converted into
a ‘poison’ or a DNA damaging agent, and not just merely from a
lack of enzyme activity (Corbett and Osheroff, 1993; Chen and
Liu, 1994; Pommier et al, 1994). The pathways committed in the
repair of DNA strand breaks generated by the inhibition of topo-
isomerase, as described above, or in response to various classes
of DNA damaging agents are now gradually being deciphered
(Chaney and Sancar, 1996; Wood, 1996; Barret and Hill, 1998).
Notably, extensive studies of the RAD52 epistasis group in yeast
have already permitted a better understanding of the molecular
mechanism(s) of recombinational repair of double-stranded DNA
breaks (Friedberg et al, 1991; Hays et al, 1995). One of the best
characterized genes in this group is RAD52 (Milne and Weaver,
1993), whose inactivation leads to a deficiency in recombination
and double-stranded DNA break repair. Persistent unresolved
double-strand breaks destabilize DNA and can lead to G2 arrest
and then, as a consequence, lethality (Bennett et al, 1997).
The possible intricate relationships existing between the mecha-
nisms of action of topoisomerases, DNA metabolism and the DNA
repair pathways revolving around the common DNA substrate
therefore suggested that the mode of action of drugs might be best
investigated in a multifactorial model in order to dissect their
potentially differential mechanism(s) of action.
In this study, we have developed a functional assay focusing on
specific molecular pathways of potential importance in the field of
chemotherapy such as those associated with the topoisomerases
and double-stranded DNA repair. Specifically, the assay is based
on analyses of the differential sensitivities of pairs of yeast with
phenotypes differing by only specific traits, namely expression or
not of either the RAD52 protein, or of the ectopic human TOP1
enzyme. Following its validation using a series of standard anti-
tumour agents, including known TOP1 and TOP2 inhibitors, as
well as DNA-damaging agents, this assay was used as a tool to
provide a better understanding of the mode of action of a series of
bisdioxopiperazines, ICRF compounds (Andoh and Ishida, 1998),
certain of which have been described as inhibitors of the catalytic
Differential expression of topoisomerase I and RAD52
protein in yeast reveals new facets of the mechanism of
action of bisdioxopiperazine compounds
B van Hille1, X Clerc1, AM Creighton2 and BT Hill1
1Division de Cancérologie, Centre de Recherche Pierre Fabre, 17 av. Jean Moulin, 81106 Castres Cédex, France; 2Medicinal Chemistry Laboratory,
Department of Reproductive Physiology, St Bartholomew’s Hospital Medical College, 51–53, Bartholomew Close, London ECIA 7BE, UK
Summary A screening procedure which permits identification of compounds based on their activities against specific biological targets
directly in a living organism, Saccharomyces cerevisiae, has been established as part of our new drug discovery programme. Use of this
assay has provided the first direct evidence that TOP1 and RAD52 proteins are involved in the mode of action of bisdioxopiperazine ICRF
compounds, which thus express a mode of action quite distinctive from the other known TOP2 inhibitors evaluated. The functional assay is
based on a comparison of pairs of yeast differing in their phenotypes by specific traits: the expression or lack of expression of ectopic human
DNA topoisomerase I, with or without that of the RAD52 gene. Amongst a series of anticancer agents, inhibitors of topoisomerase I
(camptothecin) were identified as such in yeast expressing human topoisomerase I, whilst the presence or absence of RAD52 protein
permitted the discrimination of compounds generating double-stranded DNA breaks, either directly (bleomycin) or involving DNA adduct
formation (cisplatin), or indirectly with DNA damage mediated via inhibition of the topoisomerase II enzyme (etoposide). Notably, however,
both the RAD52 protein and the lack of TOP1 enzyme appeared implicated in the cytotoxic activities of the series of bisdioxopiperazine ICRF
compounds tested. This functional assay in a living organism therefore appears to provide a valuable tool for probing distinctive and specific
mode(s) of action of diverse anticancer agents. © 1999 Cancer Research Campaign
Keywords: human; yeast; topoisomerase I; RAD52; DNA repair; bisdioxopiperazine
800
British Journal of Cancer (1999) 81(5), 800–807
© 1999 Cancer Research Campaign
Article no. bjoc.1999.0767
Received 23 February 1999
Revised 6 May 1999
Accepted 7 May 1999
Correspondence to: BT HillTOP1 and RAD52 implicated in bisdioxopiperazines cytotoxicity 801
British Journal of Cancer (1999) 81(5), 800–807 © 1999 Cancer Research Campaign
activity of TOP2 through trapping of the cleavable complexes,
after the religation of cleaved DNA ends (Roca et al, 1994;
Sehested and Jensen 1996; van Hille and Hill, 1998).
MATERIALS AND METHODS
Chemicals and drugs
Amsacrine, cisplatin and doxorubicin were purchased from Sigma
(Saint-Quentin Fallavier, France), camptothecin from Cipla Ltd
(Bombay, India), mitoxantrone from Lederle (Paris-La Défense,
France), bleomycin from Roger Bellon (Neuilly-sur-Seine,
France), ICRF-187 (dexrazoxane) from Chiron (Suresnes, France)
and fungizone from Gibco-BRL (Gaithersburg, MD, USA). The
other test compounds, i.e. 10-hydroxy-camptothecin, etoposide,
ICRF-159 (razoxane), TOP 53 and vinorelbine were provided
by Pierre-Fabre Médicament (Castres, France). ICRF-201, ICRF-
202, ICRF-186 and ICRF-193 were synthesized essentially as
described in the published literature (Creighton, 1971, 1974). Test
compounds were dissolved in 10% dimethylsulphoxide (DMSO)
obtained from Sigma (Saint-Quentin Fallavier, France), except for
cisplatin which was dissolved in 0.9% sodium chloride and, with
bleomycin, a Fe2+(NH4)2 solution was used.
Yeast strains, plasmids and construction of plasmids
The yeast strains JN394 (MATa ura3–52 leu2 trp1 ade1–2 his7
ISE2 top1::TRP RAD52::LEU2) and JN362a (MATa ura3–52 leu2
trp1 ade1–2 his7 ISE2 top1::LEU2) and the centromeric plasmid
construct pYX112-hTOP1B that allows for the overexpression of
human TOP1 under the control of the promoter TPI, were kindly
provided by Dr JL Nitiss (St Jude Children’s Research Hospital,
Memphis, TN, USA).
Strain JN394 was transformed with plasmid construct pYX112-
hTOP1B and subclones designated Y(+/–) were selected.
Similarly, subclones of yeast JN394 transformed with a plasmid
pYX112 bearing only the selective URA3 gene were also selected
and designated Y(–/–). Yeast JN362a was transformed with plas-
mids pYX112 and pRS414 so as to select a strain Y(–/+) regaining
prototrophy for, respectively, uracil and tryptophan. JN362a
was also successively transformed with the plasmids pYX112-
hTOP1B and pRS414, generating the yeast transformant Y(+/+),
so as to share the same growth requirements as the three previ-
ously selected yeast recombinants, namely, Y(+/–), Y(–/–) and
Y(–/+). These four recombinants therefore differed from each
other on the basis of the absence or overexpression of hTOP1
and/or absence or normal expression level of the RAD52 protein.
For clarity in the text, yeast recombinants developed in this study
were designated according to their phenotypic characteristic,
i.e. symbol in brackets correspond to expression (+) or not (–) of
TOP1 enzyme (left symbol) and RAD52 protein (right symbol).
The construction of yeast used in this study, along with their geno-
typic and phenotypic characteristics is detailed in Table 1.
In vivo drug screening assays
Yeast strains were stored, propagated and grown in selective
minimal media, as described earlier (Ausubel et al, 1995). Yeasts
were transformed with an electroporator (Subra model GHT
1287B, Toulouse, France) at 625 V for one pulse of 16 ms. The
assay was performed as described previously (van Hille and Hill,
1998). Briefly, yeast strains in exponential-growth phase were
adjusted to 107 cell ml–1. Thereafter, 2 ml aliquots from serial
tenfold dilutions of each culture were seeded onto agar plates
containing selective minimal media and a final concentration of
1% DMSO with or without test compound, at various concentra-
tions. Plates were incubated at 30°C for 4 days. The surface of all
the plates was then digitally processed using a ‘Geldoc 1000’ fluo-
rescent gel documentation system (Bio-Rad, Hercules, CA, USA)
and the density of yeast growth for each inoculum was quantitated
with the associated Molecular Analyst software provided.
Measurement of drug sensitivities
The effects of each drug concentration on the survival of each indi-
vidual yeast recombinant was determined as a percentage of the
growth observed on the control plate to which only DMSO had
been added. Starting with values obtained from inoculi from stock
cultures of each yeast strain, the GraphPad Prism software was
used to calculate and draw non-linear regression curves of cyto-
toxicity, with the ‘sigmoïdal dose–response (variable slope)’
mode. Regression curves for each strain were superimposed on the
same graph. The top plateau corresponds to 100% growth relative
to the control and the bottom one to 100% cytotoxicity.
Concentrations of each compound which reduced the density of
growth by 50%, IC50 values, were also calculated and used as a
measure of the cytotoxicity of each compound against an indi-
vidual yeast strain. Additionally, results from the serial dilutions of
yeast on the plates were used visually to confirm the effect of the
compound on the viability of the yeast. All results were repro-
ducible in at least two independent experiments. Furthermore,
each experiment included as controls, camptothecin and etoposide,
to check for the maintenance of, respectively, the variation in
TOP1 and RAD52 expressions, through their respective differen-
tial sensitivities.
Table 1 Characteristics of the yeast transformants used in these studies
Yeast Genotype/plasmid host Phenotypic status
transformant yTOP1 hTOP1 RAD52
JN394 MATa ura3–52 leu2 trp1 ade1–2 his7 ISE2
top1::TRP RAD52::LEU2 –––
JN362a MATa ura3–52 leu2 trp1 ade1–2 his7 ISE2
top1::LEU2 ––+
Y(+/–) as JN394 + pYX112–hTOP1B – + –
Y(–/–) as JN394 + pYX112 – – –
Y(–/+) as JN362a + pYX112 + pRS414 – – +
Y(+/+) as JN362a + pYX112-hTOP1B + pRS414 – + +802 B van Hille et al
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Comparison of the relative differences in sensitivities to a given
compound expressed by two yeast recombinants is based on
previous work examining cross-resistance in mammalian cells
(Shen et al, 1995) and yeast (van Hille and Hill, 1998). Briefly, the
respective drug-sensitivity of the four yeast transformants are
compared two-by-two, depending on the constant and variable
parameters via four different ratios R1 = [IC50 from Y(–/+)]/[IC50
from Y(+/+)], R2 = [IC50 from Y(–/–)]/[IC50 from Y (+/–)],
R3 = [IC50 from Y (–/–)]/[IC50 from Y(–/+)] and R4 = [IC50 from
Y(+/–)]/[IC50 from Y(+/+)] (Table 2). Furthermore, as demon-
strated earlier (van Hille and Hill, 1998) and confirmed in this
study (Figure 1), standard deviations did not exceed 30%.
Therefore, different sensitivities between yeasts were considered
significant when ratios were either below 0.7 or above 1.3
(Table 2).
RESULTS
Validation of the functional assay in yeast
The four yeast recombinants developed in this study, whose
phenotypic characteristics are summarized in Figure 1A, had
similar growth rates in identical media, and no deleterious effect
on their growth was shown to be exerted by up to 1% DMSO in the
agar medium (data not shown). Furthermore, following digital
processing of the surface of each agar plate, the density of yeast
growth issuing from each inoculum was quantitated and translated
into curves of growth inhibition as a function of drug concentra-
tion. Representative data for three of the antitumour agents evalu-
ated are illustrated in Figure 1B–D. The extent of the standard
deviations relating to each data point are illustrated for only one of
these test compounds, etoposide (Figure 1C), for the sake of
clarity. These values rarely exceeded 30%, possibly reflecting the
cumulative variations inherent in the preparation of stock solution
and dilutions of compounds tested, as well as the setting of agar
plates, the deposition of inoculi on these plates and of the growth
of the yeasts themselves (van Hille and Hill, 1998). Overall, the
IC50 values recorded for the different compounds tested varied
over more than two logs ranging from 0.1 to 50 mM (Table 2). It is
difficult to attribute any definite significance to these numbers,
since these IC50 values merely reflect the level of growth inhibition
induced by each test compound whose bioavailability may in fact
be limited due to: (i) the permeability barrier at the cell wall of the
yeast; this permeability appears to vary from drug to drug, as
previously described (Nitiss and Wang, 1988), and (ii) the half-life
of each test compound in the agar medium. Therefore, IC50 values
measured using yeast transformants cannot readily be compared
directly with data obtained using mammalian cells, devoid of this
cell wall. However, according to similarities in the drug-induced
patterns of differential growth inhibition identified from the ratios
R1, R2, R3 and R4 obtained with this assay, the anti-tumour
compounds tested could be classified into three separate groups
(Table 2).
Identification of inhibitors of TOP1 enzyme
Two known inhibitors of TOP1, camptothecin (Wall et al, 1966)
and 10-hydroxy-camptothecin (Kingsbury et al, 1991), were tested
in this in vivo functional assay. Both compounds induced a charac-
teristic pattern of differential growth inhibition amongst the four
yeast recombinants tested, as exemplified by the curves of growth
inhibition generated by camptothecin (Figure 1B), clearly associ-
ated with the increased expression of TOP1. These data essentially
confirm previous reports (Eng et al, 1988, Bjornsti et al, 1988).
Indeed, the growth of yeast Y(–/–) and Y(–/+) was not different
from that measured on a control plate free of test compound,
Table 2 Differential effects of a series of antitumour agents on the growth of yeast transformants differing in terms of their hTOP1 and/or RAD52 status
RAD52 – RAD52 + TOP1 – TOP1 + Constant trait
TOP1 –/+ TOP1 –/+ RAD52 –/+ RAD52 –/+ Variable trait
Y(+/–) Y(–/–) Y(–/+) Y(+/+) Y(–/+)/Y(+/+) Y(–/–)/Y(+/–) Y(–/–)/Y (–/+) Y(+/–)/Y(+/+)
IC50 IC50 IC50 IC50 Ratio R1a Ratio R2b Ratio R3c Ratio R4d
Group 1 test compound
Camptothecin 0.12 > 10 >10 0.13 >77 > 83 NE 0.9
10-Hydroxycamptothecin 1.8 > 100 >100 1.4 >71 > 55 NE 1.3
Group II test compound
Etoposide 3.3 2.9 > 100 > 100 NE 0.9 < 0.1 < 0.1
Amsacrine 52 40 > 100 > 100 NE 0.8 < 0.4 < 0.5
Mitoxantrone 4.6 6.7 > 100 > 100 NE 1.4 < 0.1 < 0.5
TOP 53 1.1 1.1 > 100 > 100 NE 1.0 <0.1 < 0.1
Bleomycin 5.8 7.9 15 15 1.0 1.4 0.5 0.4
Cisplatin 4.0 3.2 27 30 0.8 1.3 0.1 0.1
Doxorubicin 1.1 1.1 9.8 9.1 1.1 1.0 0.1 0.1
Group III test compound
ICRF-159 100 18 57 > 200 < 0.4 0.2 0.3 < 0.5
ICRF-186 29 6.8 17 > 100 < 0.2 0.2 0.4 < 0.3
ICRF-187 > 200 100 > 200 > 200 NE NE NE NE
ICRF-193 100 3.5 28 > 100 < 0.3 0.4 0.1 < 1
ICRF-201 > 100 42 > 100 > 100 NE NE NE NE
ICRF-202 15 5.6 17 > 100 < 0.2 0.4 0.3 <0.2
aRatio R1 = [IC50 from Y(–/+)]/[IC50 from Y(+/+)]; bratio R2 = [IC50 from Y(–/–)]/[IC50 from Y(+/–)]; cratio R3 = [IC50 from Y(–/–)]/[IC50 from Y(–/+)]; dratio R4 = [IC50
from Y(+/–)]/[IC50 from Y(+/+)]. IC50 values, in mM, correspond to drug concentrations that reduced the density of growth by 50%. Drug-induced differential
growth inhibition between two yeast recombinants differing by only one trait were assessed as the ratios R1, R2, R3 or R4. Depending on the ratio values
obtained, three groupings of drugs were defined: group I those with ratios R1 and R2 above 1.3; group II those with ratios R3 and R4 below 0.7, and group III
those not falling in previous two groups. NE = non evaluable.TOP1 and RAD52 implicated in bisdioxopiperazines cytotoxicity 803
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whereas the growth of yeast Y(+/–) and Y(+/+) was severely
impaired at camptothecin concentrations lower than 0.1 mM and
these growth inhibition curves were superimposable (Figure 1B).
Corresponding IC50 values were, respectively, 0.12 mM and
0.13 mM (Table 2, group I). The RAD52-independent influence of
the TOP1 status on the sensitivity of a pair of yeasts challenged
with camptothecin could be identified by examining the two ratios
of the IC50 values obtained, from pairs of yeasts exhibiting either
the wild-type RAD52 gene, i.e. R1 or a ‘knocked-out’ RAD52D
gene, i.e. R2. Values of these ratios R1 and R2 were universally
high, being above 55 for camptothecin and for 10-hydroxy-
camptothecin (Table 2, group I). In contrast, estimations of the R4
ratio showed that when comparing two yeasts expressing similar
levels of hTOP1, a difference in RAD52 expression did not alter
significantly the sensitivity of the yeast to camptothecin, with R4
values of 0.9 and 1.3. Conversely, the R3 ratio was not evaluable
in the absence of any growth inhibition of yeast transformants
Y(–/+) and Y(+/+) at the highest concentrations tested (Table 2,
group I). Overall, 10-hydroxy-camptothecin had a similar pattern
of differential sensitivities to that of camptothecin, except for its
lower potency.
Identification of RAD52-associated DNA-damaging
agents
When evaluating seven anti-tumour agents with known DNA-
damaging properties, namely amsacrine, etoposide, mitoxantrone,
TOP 53, doxorubicin, cisplatin and bleomycin (DeVita et al, 1993;
Utsugi et al, 1996), yeast transformants Y(+/–) and Y(–/–) proved
to be hypersensitive, whereas yeast Y(–/+) and Y(+/+) showed
diminished sensitivity or complete resistance at the concentrations
tested, as revealed by the IC50 values obtained (Table 2). Full data
for etoposide and cisplatin are illustrated in Figure 1C and 1D.
Based on these similarities in their patterns of differential sensitiv-
ities, these compounds were placed in group II (Table 2). More
specifically, first, the influence of the RAD52 status on the
sensitivity of a pair of yeasts challenged with these compounds,
irrespective of their TOP1 status, was evaluated through calcula-
tion of the ratio of the IC50 values obtained with two yeasts
differing only in terms of their RAD52 expression, i.e. either yeast
transformants Y(–/–) and Y(–/+) that are both devoid of TOP1
expression, or yeast Y(+/–) and Y(+/+) that both express hTOP1.
In this way the R3 and R4 ratios may be considered. Amsacrine,
etoposide, mitoxantrone, TOP 53, doxorubicin, cisplatin and
bleomycin all yielded R3 and R4 ratio values well below unity,
indicating that the integrity of RAD52 is a strong prerequisite for
the resistance of yeast to these compounds (Table 2, group II).
Interestingly, it appeared that the cytotoxicity generated by
amsacrine, etoposide, mitoxantrone and TOP 53 was strictly
dependent upon the absence of the RAD52 protein, as exemplified
by the curves of growth inhibition presented for example, for
etoposide (Figure 1C). Doxorubicin, cisplatin and bleomycin,
while also exhibiting RAD52-dependent cytotoxicity, at their
lower concentrations, totally inhibited the growth of the four yeast
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included in this functional assay when assayed at the higher range
of concentrations, as exemplified by the curves of growth inhibi-
tion induced by, for example, cisplatin (Figure 1D). Secondly, the
significance of the TOP1 status on the sensitivity of yeast in the
absence of any RAD52-associated variation, could be assessed
through an examination of the two ratios R1 and R2. In this
respect, these ratios either approximated to unity or were not
evaluable due to a general lack of cytotoxicity, indicating that the
TOP1 level did not influence drug sensitivities.
Finally, vinorelbine, a tubulin-targeting antitumour agent
(Johnson et al, 1996) was assayed as an example of a drug with no
known interaction with either DNA or with TOP1. This compound
did not alter the growth of any of the four yeasts at concentrations
≤ 100 mM (data not shown). As a further control, a standard anti-
fungal agent, the antibiotic fungizone, was shown to inhibit the
growth of all four yeast recombinants with similar efficiencies
(data not shown). Finally, the possibility was considered that
DMSO, known for its potentially antioxidant properties, might
antagonize the action of certain DNA damaging agents included in
this study, e.g. cisplatin or bleomycin. Assays were performed in
parallel with these test compounds solubilized in their preferred
solvent. Irrespective of the solvent used, comparable results were
obtained (data not shown).
Analysis of six bisdioxopiperazine derivatives
Bisdioxopiperazine compounds are catalytic inhibitors of TOP2
(Andoh and Ishida, 1998). ICRF-187 (dexrazoxane) is the (+)-(S)-
enantiomer and ICRF-186 the (–)-(R)-enantiomer of the racemic
ICRF-159 [(+/–)-1,2-bis(3,5-dioxopiperazin-1-yl)propane], while
ICRF-193, ICRF-202 and ICRF-201 are corresponding butane and
hexane derivatives (Figure 2) which possess greater potency in
mammalian cell culture and TOP2 inhibition assays (Hasinoff et
al, 1995). These six bisdioxopiperazine derivatives were assayed
at concentrations ranging from 10–4 to 10–7 M. Compounds ICRF-
159, ICRF-202, ICRF-186 and ICRF-193 induced similar, yet
distinctive, patterns of differential growth inhibition and were
therefore included as group III test compounds (Table 2). ICRF-
159 (Figure 3A) proved overall least cytotoxic of these four
compounds with IC50 values ranging from 18 to 100 mM and ICRF-
193 (Figure 3B) was most potent with IC50 values as low as 3.5 mM
for yeast transformant Y(–/–), excluding yeast Y(+/+). Indeed, the
yeast transformant Y(+/+), expressing both hTOP1 and RAD52,
appeared to show either only slight sensitivity to ICRF-159, ICRF-
202 and ICRF-186, or none at all to ICRF-193. Examining the
individual responses of the four yeast transformants to each of
these ICRF compounds in terms of their ratios of IC50 values
(Table 2), it is apparent that: (i) dual deficiencies in both TOP1 and
RAD52, as in yeast Y(–/–), resulted in transformants showing
maximal levels of sensitivities to these compounds; (ii) the loss of
a functional RAD52 protein in yeast Y(+/–) or the absence of the
TOP1 enzyme in yeast Y(–/+), provided transformants with inter-
mediate sensitivities to these compounds; (iii) the expression of
both hTOP1 and RAD52 in yeast Y(+/+) provided transformants
showing, at the highest concentrations tested, either only slight
sensitivity or no sensitivity at all to these compounds. The two
other compounds evaluated in this series, ICRF-187 and ICRF-201
appeared far less cytotoxic than ICRF-159 (Table 2, group III).
They notably impaired only the growth of yeast lacking TOP1 and
a functional RAD52, i.e. yeast transformant Y(–/–). Therefore, in
terms of overall relative effects, the order of increasing potency
was revealed as follows: ICRF-187 < ICRF-201 < ICRF-159 <
ICRF-186 < ICRF-202 < ICRF-193.
DISCUSSION
A series of standard antitumour agents tested in the described
functional assay in yeast were correctly identified according to
their known mechanism(s) of action, and therefore classified as
follows: (group I) drugs specifically inhibiting TOP1, such as
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Figure 2 Structure of bisdioxopiperazine ICRF compounds. ICRF-159:
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camptothecin and 10-hydroxycamptothecin; and (group II) drugs
altering the integrity of double-stranded DNA. This latter group
includes a number of apparently unrelated agents, although alter-
ations in double-stranded DNA have generally been implicated in
their varied mechanism(s) of action, either including interstrand
DNA adduct formation, as with cisplatin, or via double-stranded
DNA breaks as with bleomycin, or through a direct interference
with the activity of TOP2, as with etoposide, amsacrine, mito-
xantrone, TOP 53 and doxorubicin.
Furthermore, our findings show that etoposide, amsacrine,
mitoxantrone and TOP 53, whose known mode of action involves
stabilization of cleavable complexes formed by DNA and TOP2,
exert a negative effect on yeast growth only when the RAD52
locus is disrupted, i.e. on yeast recombinants Y(–/–) and Y(+/–),
but not on Y(–/+) and Y(+/+). This indicates that this set of test
compounds has a mode of action appearing mainly to rely on
TOP2-mediated induction of double-stranded DNA breaks
repairable by the RAD52-associated DNA repair mechanism. In
contrast, the mode(s) of action of bleomycin, cisplatin and doxo-
rubicin leading to growth inhibition appeared to be only partially
RAD52-dependent, since a restoration of a normal level of RAD52
protein only decreased the level of growth impairment by less than
tenfold (Table 2, ratios R3 and R4). This suggests that besides this
alteration of double-stranded DNA integrity, bleomycin, cisplatin
and doxorubicin may actually cause alternative DNA damage such
as that already known to be formed by a number of chemothera-
peutic compounds, for example monofunctional or bifunctional
adduct formation, intercalation of DNA thereby modifying the
topology of DNA, or single- or double-strand breaks repaired by
RAD52-independent epistasis groups, inhibition of other vital
enzymes, generation of toxic free radicals, etc. (Thielmann et al,
1993; Abe et al, 1994; van Rosmalen et al, 1995; Chaney and
Sancar, 1996). However, this hypothesis is only speculative, since
the lack of sensitivity of yeast to etoposide, amsacrine, mito-
xantrone and TOP 53 may actually originate from a lack of sensi-
tivity within the ranges of concentrations tested. Alternatively, the
sensitivity of RAD52-undisrupted yeast to high concentrations
of bleomycin, cisplatin and doxorubicin could result from a
hypothetical saturation of the RAD52 pathway. In terms of TOP1
inhibition, other groups have demonstrated that in the presence of
wild-type level of yTOP1, the disruption of RAD52 was associ-
ated with a higher level of sensitivity of the recipient yeast to
camptothecin (Eng et al, 1988; Nitiss and Wang, 1988). This
apparent discrepancy may be explained, at least in part, by three
non-exclusive hypotheses: firstly, experimental protocols essen-
tially differed in terms of the time factor involved (ranging from
several hours to several days) which may modify the overall
number of cells sensitive to camptothecin whose killing has an
S phase dependency. Secondly, our results may suggest a complete
inactivation, by stochiometric saturation, of the RAD52 pathways
by hTOP1, but not by yTOP1, in the presence of camptothecin.
Thus no differences in cytotoxicity are observed when RAD52 is
intact or knocked out. Thirdly, the unique genetic backgrounds
inherent to each yeast strain used in this and other studies may
actually differ in terms of, still uncharacterized, repair pathways
that may actually compensate for the lack of RAD52 protein,
notably in yeast recombinants Y(+/–). Further work will be needed
to evaluate the role of other RAD52 epistasis group components as
well as alternative repair mechanisms. Overall, this functional
assay in yeast has served readily to identify such drugs as TOP1
inhibitors and/or agents that alter the integrity of double-stranded
DNA. Notably, this functional assay has revealed that the presence
of either hTOP1 enzyme and/or a functional RAD52-dependent
double-stranded DNA repair mechanism may circumvent the
known effect(s) of bisdioxopiperazine compounds on the activity
of yeast TOP2 expressed, undisrupted, in yeast. In the case of
ICRF-193, both restoration of a functional RAD52 protein and the
expression of hTOP1 helped to restore cell growth to near normal
levels, i.e. increased the IC50 value by two logs (Figure 3). This
apparently unique pattern of differential sensitivities essentially
differed from that of all the other antitumour agents tested
(Table 2) and yet was common to all the bisdioxopiperazine deriv-
atives tested. Additionally, as shown in Figure 1C, an absence of
etoposide-induced differential sensitivity between yeast trans-
formants Y(+/–) and Y(–/–) indicated that the plasmid-driven
variation in TOP1 expression in these yeast recombinants was not
substituted by a concomitant alteration in yeast TOP2 levels.
The RAD52-related hypersensitivity to ICRF compounds of
yeast transformants Y(–/–) and Y(–/+) appear to confirm, although
using a different methodology, data reported earlier by Ishida
et al (1995) describing the differential cytotoxicity exerted by
ICRF-159 on the yeast strains SAR and SAR52. Furthermore,
there appears relative concordance, between the order of cytotoxic
potency identified using this yeast functional assay and earlier
reported data from mammalian cell culture assays (Hasinoff et al,
1995), with ICRF-202 and ICRF-193 proving the most potent
and ICRF-187 and ICRF-159 the least potent derivatives. The rela-
tively lower activity exerted by ICRF-187 versus its enantiomer
ICRF-186, unlike earlier results from mammalian systems
(Hasinoff et al, 1995), may be indicative of differential species-
specific bio-availability or enzymatic processing/inactivation of
ICRF compounds. Notably, it is possible that one isomer is more
sensitive to hydrolysis (causing inactivation of TOP2 activity) by
the dihydropyrimidine aminohydrolase (DHPase) present in yeast,
since it has been shown that bovine liver DHPase enzyme can
hydrolyse one ring of ICRF-187, although effects on ICRF-186
were not investigated (Hasinoff et al, 1991).
Bisdioxopiperazine compounds are known to be catalytic
inhibitors of TOP2 exerting their effects at a late stage of the
catalytic cycle of the enzyme, neither causing DNA breaks nor
intercalating DNA (Sehested et al, 1993; Sehested and Jensen,
1996). In these respects they differ from other TOP2 inhibitors that
stabilize cleavable complexes, such as etoposide or amsacrine
(Corbett and Osheroff, 1993). Indeed, bisdioxopiperazines are
considered to induce DNA-bound TOP2 enzyme into a closed-
clamp form that consequently triggers the further processing of
DNA, notably chromosomal condensation and decondensation
(Roca et al, 1994). Based on the novel results presented here,
a revised mechanism of action of these bisdioxopiperazine ICRF
compounds can be proposed tentatively. It can be concluded that
ICRF compound-induced DNA-TOP2 complexes lead, directly
or indirectly, to DNA lesions recognized by the RAD52-
associated repair pathway. In addition, it appears that the absence
of the TOP1 enzyme is associated with increased sensitivity to
these bisdioxopiperazines. Indeed, if TOP1 is dispensable in yeast,
its absence in cells is compensated by the activity of TOP2
enzyme. However, this leads to a TOP2 enzyme expressing
functions and acting on DNA at sites that are not its ‘normal’
targets. One may therefore hypothesize that, within this in vivo
cellular model, bisdioxopiperazines compounds essentially differ
from the other TOP2-interacting compounds tested in that they
preferentially target these ‘illegitimate’ functions of the TOP2enzyme that are implicated as a result of down-regulation of the
TOP1 enzyme.
These bisdioxopiperazines therefore provide examples of anti-
tumour drugs with pleiotropic mechanisms of action and of poten-
tial therapeutic importance, since, in addition to their known
TOP2-mediated interactions, they appear able preferentially to
impair the growth of yeast with altered DNA repair mechanisms
(Chaney and Sancar, 1996), and/or decreased TOP1 expression,
a phenotype implicated in resistance to TOP1 inhibitors (Pinedo
et al, 1997).
In conclusion, the set of isogenic yeast recombinant developed
in this study allows for the unequivocal discrimination of hTOP1
inhibitors inducing single-stranded DNA breaks, i.e. whose
actions are not reparable by RAD52-dependent mechanisms, from
TOP2 inhibitors and other double-stranded DNA breaking agents.
Furthermore, this functional assay in yeast has proved useful in
permitting a detailed dissection of the mechanism of action of a
series of bisdioxopiperazine ICRF compounds, providing the first
direct evidence that the cytotoxic activity of TOP2-inhibiting
bisdioxopiperazine derivatives is associated with double-stranded
DNA breaks recoverable by the RAD52-dependent epistasis
group, and is modulated by the activity of the TOP1 enzyme.
Bisdioxopiperazines therefore possess an apparent mode of action
quite distinctive from other known TOP2 inhibitors evaluated.
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